- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01207687
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
Phase 2 Study of Bevacizumab in Children and Adults With Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. The primary objective of this study is to determine the activity of bevacizumab for treatment of symptomatic vestibular schwannomas (VS) defined as progressive hearing loss in patients with neurofibromatosis type 2 (NF2) based on objective hearing response.
SECONDARY OJBECTIVES:
I. Determine the safety and tolerability of bevacizumab in this patient population on an every three week dosing schedule of 7.5mg/kg for 12 months of therapy.
II. Assess the rate of radiographic response (>= 20% reduction in volume). III. Determine the growth rate of VS using volumetric MRI analysis in comparison to 1-dimensional and 2-dimensional measurements.
IV. Assess changes in function of the auditory system during bevacizumab treatment.
V. Assess the vascular permeability (Ktrans), relative cerebral blood volume/flow, mean transit time, and mean vessel diameter from perfusion-weighted MRI.
VI. Assess the change in circulating endothelial cells, circulating progenitor cells, and plasma angiogenic proteins in subjects receiving bevacizumab treatment.
VII. Observe the impact of bevacizumab on non-VS tumors in patients with NF2 via whole body MRI.
VIII. Explore hearing related QOL measures throughout treatment. IX. Explore the effect of treatment with bevacizumab on auditory function using distortion product optoacoustic emissions (DPOAE) (to be evaluated at NCI only).
OUTLINE:
Patients receive bevacizumab intravenously (IV) over 30-90 minutes once every 3 weeks. Courses repeat every 6 weeks for up to 48 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 3 and 6 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Rockville, Maryland, United States, 20850
- National Cancer Institute
-
-
Massachusetts
-
Charlestown, Massachusetts, United States, 02129
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must have a confirmed diagnosis of neurofibromatosis 2 by fulfilling National Institute of Health (NIH) criteria or Manchester criteria, or by detection of a causative mutation in the NF2 gene
The NIH criteria (82) includes presence of:
- Bilateral vestibular schwannomas, OR
- First-degree relative with NF2 and EITHER unilateral eighth nerve mass OR two of the following: neurofibroma, meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity
The Manchester criteria (101) includes presence of:
- Bilateral vestibular schwannomas, OR
- First-degree relative with NF2 and EITHER unilateral eighth nerve mass OR two of the following: neurofibroma, meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity, OR
- Unilateral vestibular schwannoma AND any two of: neurofibroma, meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity, OR
- Multiple meningiomas (two or more) AND unilateral vestibular schwannoma OR any two of: schwannoma, glioma, neurofibroma, cataract
- Patients must have measurable disease, defined as at least one VS >= 1.5 cm (on longest diameter) as measured by contrast-enhanced cranial MRI scan with fine cuts through the internal auditory canal (3 mm slices, no skip)
- Life expectancy of greater than 6 months
- ECOG performance status (Karnofsky >= 60% or Lansky Score >= 60)
- Patients must have normal organ and marrow function as defined below:
- Leukocytes >= 3,000/mcL
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 150,000/mcL or lower limit of institutional normal
- Total bilirubin =< 2 X institutional upper limit of normal
- AST(SGOT)/ALT(SGPT) =< 2.5 X institutional upper limit of normal
- Patients must have recovered from acute toxicity of prior treatment to grade 1 or less unless otherwise specified
Patients must have a creatinine clearance or radioisotope GFR >= 60ml/min/1.73 m^2 or a normal serum creatinine based on age described in the table below:
- Age(years) =< 5: 0.8 mg/dL
- 5 < age (years) =< 10: 1.0 mg/dL
- 10 < age (years) =< 15: 1.2 mg/dL
- Age (years) > 15: 1.5 mg/dL
- Subjects must have a VS not amenable to surgery or have refused surgery due to high risk for permanent complications related to surgery (e.g. damage to lower cranial nerve function, facial palsy, risk for cerebrospinal fluid leak, etc.) as determined by a surgeon with experience in management of NF2 associated VS
- Subjects must have had a discussion of all available treatment options and their risks and benefits of these options including surgery, radiation therapy, observation, other clinical trials and expressed their preference for participation in this trial in the informed consent process
- The effects of bevacizumab on the developing human fetus at the recommended therapeutic dose are unknown; for this reason and because anti-angiogenic agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Ability to understand and the willingness give written informed consent or assent
- Evidence of active disease, defined as progressive hearing loss (with decrease in word recognition score) related to VS (i.e., not due to prior interventions such as surgery or radiation) documented in the preceding 24 months with a word recognition score of < 90% in the target ear
- Proteinuria (including albuminuria) should be screened for by either urine analysis for urine protein creatinine (UPC) ratio or by urine dipstick; if the UPC ratio is greater than or equal to 0.5 or if urine dipstick shows 2+ proteinuria, 24-hour urine protein should be obtained and the level should be < 1000 mg for patient enrollment
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- Patients may not be receiving any other investigational agents
- Patients with nervous system tumors associated with NF2 (e.g., schwannomas, meningiomas, ependymomas, or gliomas) will not be excluded from this clinical trial as long as these tumors do not require treatment with radiation, surgery, or medical treatment at the time of enrollment on trial
- Patients with known hypersensitivity of Chinese hamster ovary cell products, other recombinant human antibodies, or compounds of similar chemical or biologic composition to bevacizumab
- Inability to tolerate periodic MRI scans or gadolinium contrast without general anesthesia
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements
Clinically significant cardiovascular disease, such as:
- Inadequately controlled HTN (adult subjects: SBP > 160 mmHg and/or DBP > 90 mmHg despite antihypertensive medication, pediatric subjects: Requirement for antihypertensive treatment prior to enrollment, or diastolic blood pressure > 95th percentile for age)
- History of CVA within 12 months
- Myocardial infarction or unstable angina within 12 months
- New York heart association grade II or greater congestive heart failure
- Serious and inadequately controlled cardiac arrhythmia
- Significant vascular disease (e.g. aortic aneurysm, history of aortic dissection)
- Clinically significant peripheral vascular disease
Pregnant women (positive pregnancy test) are excluded from this study because bevacizumab is an anti-angiogenic agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with bevacizumab, breastfeeding should be discontinued if the mother is treated with bevacizumab; both fertile men and women must agree to use adequate contraceptive measures during study therapy and for at least 6 months after the completion of bevacizumab therapy; abstinence is considered an adequate contraceptive measure
- In the event that a minor (age 12-17) who undergoes a pregnancy test as part of the screening process receives a positive result, they will be excluded from the study and their parent(s) of record will be notified of this result
- HIV-positive patients or cancer survivors are eligible for this study if they fulfill all other eligibility criteria
- Inability to perform volumetric measurement of target VS (e.g., due to the MRI artifact from auditory brainstem implant or due to presence of collision tumor (two or more tumors abutting each other) in the cerebellopontine angle); Note: questions about the ability to perform volumetric analysis on a baseline MRI scan should be directed to the study radiologist, Dr. Gregory Sorensen
- Concurrent use of anti-coagulant drugs (not including prophylactic doses), history of coagulopathy, or evidence of bleeding diathesis or coagulopathy
- Imaging (CT or MRI) evidence of newly identified hemorrhage (new within the last in the 6 months prior to enrollment), any history of symptomatic intracranial hemorrhage, or any history of spontaneous intracranial hemorrhage
- Serious or non-healing wound, ulcer or bone fracture
- History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to day 1
Invasive procedures defined as follows:
- Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1 therapy
- Brain biopsy within 28 days prior to day 1 of therapy (wounds must be fully healed from brain biopsies performed more than 28 days prior to day 1 of therapy)
- Anticipation of need for major surgical procedures during the course of the study
- Core biopsy within 7 days prior to D1 therapy
- Prior treatment with bevacizumab or other VEGF targeting therapies
- Personal history of autoimmune coagulopathy, including idiopathic thrombocytopenia purpura (ITP)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (bevacizumab)
Patients receive bevacizumab IV over 30-90 minutes once every 3 weeks.
Courses repeat every 6 weeks for up to 48 weeks in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Given IV
Other Names:
Ancillary studies
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Patients With Hearing Response
Time Frame: Baseline to 12 months
|
A hearing response was defined as increased word recognition score above the 95% critical threshold that is maintained across two sequential evaluation time points.
The word recognition score (WRS) is the percentage of phonetically-balanced, monosyllabic words that a patient can accurately repeat presented at either most comfortable level or most intelligible level.The proportion of patients with hearing response in the target ear was estimated using a binomial distribution along with 95% confidence intervals.
|
Baseline to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Serious or Life Threatening Toxicities
Time Frame: Up to 6 months post-treatment
|
The number of patients with serious or life threatening toxicities (CTCAE grade 3 or above)
|
Up to 6 months post-treatment
|
Radiographic Response
Time Frame: Baseline to 6 months post-treatment
|
The proportion of participants with radiographic response as measured by a >/= 20% reduction in tumor volume from baseline on MRI imaging will be estimated using a binomial distribution.
|
Baseline to 6 months post-treatment
|
Median Percent Change in Target Vestibular Schwannoma Volume Using Volumetric MRI
Time Frame: Baseline to 12 months
|
The median percent change in the volume of the target vestibular schwannoma using volumetric MRI
|
Baseline to 12 months
|
Number of Participants With Changes in Function of the Auditory System
Time Frame: Baseline to 6 months post-treatment
|
The primary distortion product optoacoustic emissions (DPOAE) measurement will be treated non-parametrically (present or absent across time) DPOAE's will be considered present at the frequency of F2 when the distortion product is 6dB above the noise floor.
Variables will be analyzed for differences using t-tests if the effects and sample sizes warrant, but this may not be advisable given the small numbers to be accrued.
|
Baseline to 6 months post-treatment
|
Percent Change in Median Vascular Permeability (Ktrans)
Time Frame: Baseline to week 72
|
Correlation assessment were planned for imaging parameters and hearing response based on the estimated changes in Ktrans: a MRI measure of vascular permeability.
Only 1/14 participants had complete Ktrans data that was amenable to analysis at baseline and week 72.
Hence, these statistical analyses were not possible.
|
Baseline to week 72
|
Quality of Life Assessed Using Health Survey Short Form-36 (SF-36) - Total Score
Time Frame: Baseline
|
The SF-36 is a patient reported outcome.
SF-36 (v.1) was administered and was scored according to instructions found on the RAND website.
The range of scores is 0 - 100, with a higher value indicating a more favorable health state.
The total score is the median of the all the individual items.
|
Baseline
|
Quality of Life Assessed Using Health Survey Short Form-36 (SF-36) - Component Scores
Time Frame: Baseline
|
The SF-36 is a patient reported outcome.
SF-36 (v.1) was administered and was scored according to instructions found on the RAND website.
The range of scores is 0 - 100, with a higher value indicating a more favorable health state.
Scores are commonly reported as a physical component summary (PCS) and mental component summary (MCS).
The PCS and MCS score have been transformed to the T-score metric, which has a mean of 50 and a standard deviation of 10 for the U.S. general population.
|
Baseline
|
Quality of Life Assessed Using Health Survey Short Form-36 (SF-36) - Total Score
Time Frame: 6 months
|
The SF-36 is a patient reported outcome.
SF-36 (v.1) was administered and was scored according to instructions found on the RAND website.
The range of scores is 1 - 100, with a higher value indicating a more favorable health state.
The total score is the median of the all the individual items.
|
6 months
|
Quality of Life Assessed Using Health Survey Short Form-36 (SF-36) - Component Scores
Time Frame: 6 months
|
The SF-36 is a patient reported outcome.
SF-36 (v.1) was administered and was scored according to instructions found on the RAND website.
The range of scores is 0 - 100, with a higher value indicating a more favorable health state.
Scores are commonly reported as a physical component summary (PCS) and mental component summary (MCS).
The PCS and MCS score have been transformed to the T-score metric, which has a mean of 50 and a standard deviation of 10 for the U.S. general population.
|
6 months
|
Quality of Life Assessed Using Health Survey Short Form-36 (SF-36) - Total Score
Time Frame: 12 months
|
The SF-36 is a patient reported outcome.
SF-36 (v.1) was administered and was scored according to instructions found on the RAND website.
The range of scores is 0 - 100, with a higher value indicating a more favorable health state.
The total score is the median of the all the individual items.
|
12 months
|
Quality of Life Assessed Using Health Survey Short Form-36 (SF-36) - Component Scores
Time Frame: 12 months
|
The SF-36 is a patient reported outcome.
SF-36 (v.1) was administered and was scored according to instructions found on the RAND website.
The range of scores is 0 - 100, with a higher value indicating a more favorable health state.
Scores are commonly reported as a physical component summary (PCS) and mental component summary (MCS).
The PCS and MCS score have been transformed to the T-score metric, which has a mean of 50 and a standard deviation of 10 for the U.S. general population.
|
12 months
|
Quality of Life Assessed Using Health Survey Short Form-36 (SF-36) - Total Score
Time Frame: 18 months
|
The SF-36 is a patient reported outcome.
SF-36 (v.1) was administered and was scored according to instructions found on the RAND website.
The range of scores is 0 - 100, with a higher value indicating a more favorable health state.
The total score is the median of the all the individual items.
|
18 months
|
Quality of Life Assessed Using Health Survey Short Form-36 (SF-36) - Component Scores
Time Frame: 18 months
|
The SF-36 is a patient reported outcome.
SF-36 (v.1) was administered and was scored according to instructions found on the RAND website.
The range of scores is 0 - 100, with a higher value indicating a more favorable health state.
Scores are commonly reported as a physical component summary (PCS) and mental component summary (MCS).
The PCS and MCS score have been transformed to the T-score metric, which has a mean of 50 and a standard deviation of 10 for the U.S. general population.
|
18 months
|
Quality of Life as Assessed by the Speech and Spatial Qualities Questionnaire (SSQ)
Time Frame: baseline
|
The SSQ is a 49 item patient-reported outcome with three subscales: speech understanding (14 questions), spatial location of sounds (17 questions), and the qualities of sounds (18 questions) as they appear to the patient with hearing impairment.
Each response is recorded on an 11 point scale (0 - 10), with the anchor points "not at all" (= 0) and "perfectly" (=10).
A higher score indicates better hearing.
The median score is reported for each subscale.
The minimum and maximum scores for the median of each subscale would be 0 and 10, respectively.
|
baseline
|
Quality of Life as Assessed by the Speech and Spatial Qualities Questionnaire (SSQ)
Time Frame: 6 months
|
The SSQ is a 49 item patient-reported outcome with three subscales: speech understanding (14 questions), spatial location of sounds (17 questions), and the qualities of sounds (18 questions) as they appear to the patient with hearing impairment.
Responses are recorded on a scale from 0 - 10, with the anchor points "not at all" (= 0) and "perfectly" (=10).
A higher score indicates better hearing.
The median score for each subscale is reported.
The minimum and maximum scores for the median of each subscale would be 0 and 10, respectively.
|
6 months
|
Quality of Life as Assessed by the Speech and Spatial Qualities Questionnaire (SSQ)
Time Frame: 12 months
|
The SSQ is a 49 item patient-reported outcome with three subscales: speech understanding (14 questions), spatial location of sounds (17 questions), and the qualities of sounds (18 questions) as they appear to the patient with hearing impairment.
Responses are recorded on a scale from 0 - 10, with the anchor points "not at all" (= 0) and "perfectly" (=10).
A higher score indicates better hearing.
The median score for each subscale is reported.
The minimum and maximum scores for the median of each subscale would be 0 and 10, respectively.
|
12 months
|
Quality of Life as Assessed by the Speech and Spatial Qualities Questionnaire (SSQ)
Time Frame: 18 months
|
The SSQ is a 49 item patient-reported outcome with three subscales: speech understanding (14 questions), spatial location of sounds (17 questions), and the qualities of sounds (18 questions) as they appear to the patient with hearing impairment.
Responses are recorded on a scale from 0 - 10, with the anchor points "not at all" (= 0) and "perfectly" (=10).
A higher score indicates better hearing.
The median score for each subscale is reported.
The minimum and maximum scores for the median of each subscale would be 0 and 10, respectively.
|
18 months
|
Quality of Life Assessed by the Tinnitus Reaction Questionnaire (TRQ)
Time Frame: baseline
|
The TRQ is a 26 item patient reported outcome.
It is scored using a 5 point Likert scale (0-4).
The responses are summed, resulting in a range of 0 - 104 with higher scores indicating more distress related to tinnitus.
|
baseline
|
Quality of Life Assessed by the Tinnitus Reaction Questionnaire (TRQ)
Time Frame: 6 months
|
The TRQ is a 26 item patient reported outcome.
It is scored using a 5 point Likert scale (0-4).
The responses are summed, resulting in a range of 0 - 104 with higher scores indicating more distress related to tinnitus.
|
6 months
|
Quality of Life Assessed by the Tinnitus Reaction Questionnaire (TRQ)
Time Frame: 12 months
|
The TRQ is a 26 item patient reported outcome.
It is scored using a 5 point Likert scale (0-4).
The responses are summed, resulting in a range of 0 - 104 with higher scores indicating more distress related to tinnitus.
|
12 months
|
Quality of Life Assessed by the Tinnitus Reaction Questionnaire (TRQ)
Time Frame: 18 months
|
The TRQ is a 26 item patient reported outcome.
It is scored using a 5 point Likert scale (0-4).
The responses are summed, resulting in a range of 0 - 104 with higher scores indicating more distress related to tinnitus.
|
18 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jaishri Blakeley, Johns Hopkins University/Sidney Kimmel Cancer Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Genetic Diseases, Inborn
- Neuromuscular Diseases
- Otorhinolaryngologic Neoplasms
- Otorhinolaryngologic Diseases
- Neurodegenerative Diseases
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Peripheral Nervous System Diseases
- Ear Diseases
- Nervous System Neoplasms
- Heredodegenerative Disorders, Nervous System
- Neoplastic Syndromes, Hereditary
- Cranial Nerve Diseases
- Neuroendocrine Tumors
- Nerve Sheath Neoplasms
- Neurocutaneous Syndromes
- Peripheral Nervous System Neoplasms
- Cranial Nerve Neoplasms
- Neuroma
- Vestibulocochlear Nerve Diseases
- Retrocochlear Diseases
- Neurofibromatoses
- Neurofibromatosis 1
- Neurofibroma
- Neurofibromatosis 2
- Neurilemmoma
- Neuroma, Acoustic
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Antibodies
- Immunoglobulins
- Bevacizumab
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
Other Study ID Numbers
- NCI-2012-02987 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- P30CA006973 (U.S. NIH Grant/Contract)
- J1002
- NA_00034732 (Other Identifier: Johns Hopkins University/Sidney Kimmel Cancer Center)
- 8248 (Other Identifier: CTEP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurofibromatosis Type 2
-
NYU Langone HealthNovartis Pharmaceuticals; The Children's Tumor FoundationCompletedNeurofibromatosis Type IIUnited States
-
Massachusetts Eye and Ear InfirmaryRecruiting
-
National Institute of Neurological Disorders and...Recruiting
-
Manchester University NHS Foundation TrustCompletedNeurofibromatosis Type 2United Kingdom
-
PTC TherapeuticsUnited States Department of DefenseTerminated
-
Recursion Pharmaceuticals Inc.RecruitingNeurofibromatosis Type 2United States
-
Jonsson Comprehensive Cancer CenterNovartis PharmaceuticalsTerminatedNeuroma, Acoustic | Neurofibromatosis Type 2United States
-
NYU Langone HealthCompletedNeurofibromatosis Type 2 | Vestibular SchwannomasUnited States
-
Li PengBetta Pharmaceuticals Co., Ltd.CompletedNeurofibromatosis Type 2 | Vestibular SchwannomaChina
-
Beijing Tiantan HospitalShandong Simcere-Medgenn Bio-pharmaceutical Co., LtdCompletedNeurofibromatosis Type 2 | Vestibular SchwannomaChina
Clinical Trials on laboratory biomarker analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States